Fresenius Kabi USA, LLCAugust 12, 2019

FDA 483 - Fresenius Kabi USA, LLC - August 12, 2019

View on Dashboard

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Fresenius Kabi USA, LLC

Record Details

Fresenius Kabi USA, LLC, a sterile drug manufacturer in Grand Island, NY, received a Form 483 with two observations. The firm failed to establish adequate control procedures for manufacturing processes, specifically regarding the evaluation of decontamination effects on drug product compatibility. Additionally, the quality control unit did not perform timely reviews of analytical data, leading to issues with impurity results for Vancomycin products.

Company: Fresenius Kabi USA, LLC
Inspection Date: August 12, 2019
Product Type: Drugs
Office: New Jersey District Office
People: Johana P Brea
Marcellinus D. Dordunoo (Investigator)
Rajiv R. Srivastava (Consumer Safety Officer)

Open in Dashboard

ID · 90344142-2ce1-4a03-96d2-df8dfafa023e